Safety and Efficacy Study of NVC-422 on Bacteriuria in Catheterized Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Asymptomatic Bacteriuria
Interventions
DRUG

sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate

0.1% NVC-422 in saline, up to 100 mL, Study Part 1 - once on Day 1 held in the bladder for 1 hour; Study Part 2 (Part 2a - 0.1% NVC-422, Part 2b - 0.2% NVC-422), once daily for 7 days, held in the bladder for 1 hour

Trial Locations (1)

77030

Michael E. Debakey V.A. Medical Center, Houston

Sponsors
All Listed Sponsors
lead

NovaBay Pharmaceuticals, Inc.

INDUSTRY